Plasma gelsolin levels decrease in diabetic state and increase upon treatment with F-actin depolymerizing versions of gelsolin

Journal of Diabetes Research

Volumn 2014, Issue , 2014, Pages

  Khatri, Neeraj ^a   Sagar, Amin ^a   Peddada, Nagesh ^a   Choudhary, Vikas ^a   Chopra, Bhupinder Singh ^a   Garg, Veena ^b   Garg, Renu ^a   Ashish, ^a  

^a INSTITUTE OF MICROBIAL TECHNOLOGY   (India)

^b BANASTHALI UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

F ACTIN; GELSOLIN; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; RECOMBINANT PROTEIN; SITAGLIPTIN; ACTIN; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; GLUCOSE BLOOD LEVEL; PEPTIDE FRAGMENT; PYRAZINE DERIVATIVE; STREPTOZOCIN; TRIAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD SAMPLING; BODY WEIGHT; CLINICAL ARTICLE; CONTROLLED STUDY; DEPOLYMERIZATION; DIABETIC PATIENT; DRUG EFFICACY; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; LIPID DIET; LOCOMOTION; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; SINGLE DRUG DOSE; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; TREATMENT DURATION; ADULT; ANIMAL; BLOOD; C57BL MOUSE; CASE CONTROL STUDY; CHEMICALLY INDUCED; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DOWN REGULATION; DRUG EFFECTS; GENETICS; METABOLISM; POLYMERIZATION; TIME;

ACTINS; ADULT; ANIMALS; BIOMARKERS; BLOOD GLUCOSE; CASE-CONTROL STUDIES; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DIET, HIGH-FAT; DOWN-REGULATION; FEMALE; GELSOLIN; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MICE; MICE, INBRED C57BL; PEPTIDE FRAGMENTS; POLYMERIZATION; PYRAZINES; RECOMBINANT PROTEINS; SITAGLIPTIN PHOSPHATE; STREPTOZOCIN; TIME FACTORS; TRIAZOLES;

EID: 84912137515     PISSN: 23146745     EISSN: 23146753     Source Type: Journal    
DOI: 10.1155/2014/152075     Document Type: Article

References (16)

1. Peddada N., Sagar A., Ashish, Garg R., Plasma gelsolin: a general prognostic marker of health. Medical Hypotheses 2012 78 2 203 210 10.1016/j.mehy.2011.10.024 2-s2.0-84855191919
2. Smith D. B., Janmey P. A., Sherwood J. A., Howard R. J., Lind S. E., Decreased plasma gelsolin levels in patients with Plasmodium falciparum malaria: a consequence of hemolysis? Blood 1988 72 1 214 218 2-s2.0-0023806916
3. Christofidou-Solomidou M., Scherpereel A., Solomides C. C., Christie J. O., Stossel T. P., Goelz S., DiNubile M. J., Recombinant plasma gelsolin diminishes the acute inflammatory response to hyperoxia in mice. Journal of Investigative Medicine 2002 50 1 54 60 10.2310/6650.2002.33518 2-s2.0-0036155795
4. Smith D. B., Janmey P. A., Lind S. E., Circulating actin-gelsolin complexes following oleic acid-induced lung injury. The American Journal of Pathology 1988 130 2 261 267 2-s2.0-0023868342
5. Lee P.-S., Waxman A. B., Cotich K. L., Chung S. W., Perrella M. A., Stossel T. P., Plasma gelsolin is a marker and therapeutic agent in animal sepsis. Critical Care Medicine 2007 35 3 849 855 10.1097/01.CCM.0000253815.26311.24 2-s2.0-33947164459
6. Cohen T. S., Bucki R., Byfield F. J., Ciccarelli N. J., Rosenberg B., DiNubile M. J., Janmey P. A., Margulies S. S., Therapeutic potential of plasma gelsolin administration in a rat model of sepsis. Cytokine 2011 54 3 235 238 10.1016/j.cyto.2011.02.006 2-s2.0-79955156157
7. Endres M., Fink K., Zhu J., Neuroprotective effects of gelsolin during murine stroke. The Journal of Clinical Investigation 1999 103 3 347 354 10.1172/JCI4953 2-s2.0-0032959847
8. Nelson T. Y., Boyd A. E. III, Gelsolin, a Ca2+-dependent actin-binding protein in a hamster insulin-secreting cell line. The Journal of Clinical Investigation 1985 75 3 1015 1022 10.1172/JCI111762 2-s2.0-0021895206
9. Tomas A., Yermen B., Min L., Pessin J. E., Halban P. A., Regulation of pancreatic β -cell insulin secretion by actin cytoskeleton remodelling: Role of gelsolin and cooperation with the MAPK signalling pathway. Journal of Cell Science 2006 119 10 2156 2167 10.1242/jcs.02942 2-s2.0-33745201223
10. Yermen B., Tomas A., Halban P. A., Pro-survival role of gelsolin in mouse β -cells. Diabetes 2007 56 1 80 87 10.2337/db06-0769 2-s2.0-33847047882
11. Tomas A., Yermen B., Regazzi R., Pessin J. E., Halban P. A., Regulation of insulin secretion by phosphatidylinositol-4,5-bisphosphate. Traffic 2010 11 1 123 137 10.1111/j.1600-0854.2009.00996.x 2-s2.0-71849105040
12. Kalwat M. A., Wiseman D. A., Luo W., Wang Z., Thurmond D. C., Gelsolin associates with the N terminus of syntaxin 4 to regulate insulin granule exocytosis. Molecular Endocrinology 2012 26 1 128 141 10.1210/me.2011-1112 2-s2.0-84855213751
13. 2+ insensitivity of the first half. The Journal of Biological Chemistry 2013 288 39 28266 28282 10.1074/jbc.M113.463224 2-s2.0-84884777792
14. Conarello S. L., Jiang G., Mu J., Glucagon receptor knockout mice are resistant to diet-induced obesity and streptozotocin-mediated beta cell loss and hyperglycaemia. Diabetologia 2007 50 1 142 150 10.1007/s00125-006-0481-3 2-s2.0-33845919110
15. Karasawa H., Nagata-Goto S., Takaishi K., Kumagae Y., A novel model of type 2 diabetes mellitus based on obesity induced by high-fat diet in BDF1 mice. Metabolism: Clinical and Experimental 2009 58 3 296 303 10.1016/j.metabol.2008.09.028 2-s2.0-59649102214
16. Bassil M. S., Gougeon R., Muscle protein anabolism in type 2 diabetes. Current Opinion in Clinical Nutrition and Metabolic Care 2013 16 1 83 88 10.1097/MCO.0b013e32835a88ee 2-s2.0-84871927825